Evidence map›Paper›PMID 37350806›Full record

ReviewWorld journal of oncology2023

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review.

Nosakhare Paul Ilerhunmwuwa, Mustafa Wasifuddin, Jamal Perry, Narek Hakobyan, Lawrence Inyang, Zhanna Zavgorodneva, Lilit Gasparyan, Muhammad Tahir

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nosakhare Paul IlerhunmwuwaInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Mustafa WasifuddinInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Jamal PerryInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Narek HakobyanInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Lawrence InyangInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Zhanna ZavgorodnevaInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Lilit GasparyanInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Muhammad TahirInternal Medicine Department, Brookdale Hospital Medical Center/One Brooklyn Health, Brooklyn, NY, USA.
Brookdale University Hospital and Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pituitary metastasis (PM) from differentiated thyroid cancer (DTC) is extremely rare and may adversely affect outcomes. We aimed to assess the characteristics and outcomes of patients with PM from DTC. Methods: We systematically reviewed the literature on publications on PM and the different DTC histologic types (papillary, follicular, and Hurthle cell cancers). Three databases (PubMed, Embase, and Scopus) were searched for articles published from 1967 to 2022. Survival time was estimated as the period from the first treatment of PM to the time of death or last follow-up. Results: Twenty-five articles comprising 27 cases that met the eligibility criteria were identified using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The median age of the patients was 60 years (23 - 86). A preponderance of females (66.7%) with PM most commonly reported papillary thyroid cancer (55.6%). This was followed by follicular thyroid cancer (37.0%) and Hurthle cell cancer (7.4%). The most common presentations were headache, nausea, and vomiting, with visual symptoms in 44.4%. Diabetes insipidus was an infrequent finding (7.4%). The median time from diagnosis or first treatment of DTC to the diagnosis of PM was 3 years (0 - 25). The most common endocrine abnormality was hyperprolactinemia (63.2%), while the most frequently deficient hormone was luteinizing hormone (50%). The most common treatment modality for PM was a combination of radiotherapy and surgery with or without radio-iodine. At the end of the follow-up, 30% of the patients died. Only 33.3% of the patients achieved complete resolution of symptoms. The overall median survival time was 12 months (3 - 108). There was a moderate inverse correlation between the age of patients and survival, which was, however, not statistically significant (rs = -0.45, P = 0.103). Conclusion: PM from DTC is extremely rare, and Hurtle cell cancer appears to be the least associated with PM. Diabetes insipidus is a rare initial manifestation of PM from DTC. Complete resolution of symptoms is less likely to be achieved in PM from DTC. Older age may confer an increased survival tendency, probably due to more intracranial space volume in older people compared to the younger population. Larger studies are needed to examine the relationship between age and survival in PM from DTC. Also, more observational data are required to determine the predictors of survival and compare the efficacy of the different treatment modalities in patients with PM from DTC.

Indexed as

Differentiated thyroid cancerFollicular thyroid cancerHurthle cell thyroid cancerPapillary thyroid cancerPituitary metastasisSystematic review

Identifiers

PMID37350806
PMCPMC10284638
OpenAlexW4380265337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.